Donate

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]

Dr. Mark Scholz Discusses Treatment Issues For Advanced Prostate Cancer

At the recent 2011 Prostate Cancer Research Institute Dr. Mark Scholz discussed care issues for men with advanced metastatic prostate cancer. In his presentation he stressed the importance of closely monitoring each man’s individual, on-going response to treatment to determine its effectiveness. He made a case that without close monitoring; treatment decisions would lag behind [...]

Malecare’s Advanced Prostate Cancer Program

Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]

On the Horizon- Custirsen for Men with Advanced Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]

Go to Top